Brokerages Set RAPT Therapeutics, Inc. (NASDAQ:RAPT) PT at $24.67

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) have received a consensus rating of “Hold” from the thirteen brokerages that are currently covering the company, MarketBeat.com reports. Nine investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $24.67.

A number of research firms have commented on RAPT. HC Wainwright reaffirmed a “neutral” rating on shares of RAPT Therapeutics in a report on Wednesday, April 10th. Wolfe Research reaffirmed a “peer perform” rating on shares of RAPT Therapeutics in a report on Tuesday, May 14th. Barclays cut shares of RAPT Therapeutics from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $13.00 to $4.00 in a research report on Friday, May 10th. JPMorgan Chase & Co. reduced their price target on shares of RAPT Therapeutics from $15.00 to $13.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 27th. Finally, Guggenheim cut shares of RAPT Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 10th.

RAPT Therapeutics Price Performance

Shares of RAPT Therapeutics stock opened at $3.14 on Tuesday. The firm has a market cap of $109.60 million, a P/E ratio of -1.02 and a beta of 0.40. The firm has a 50 day simple moving average of $5.41 and a 200 day simple moving average of $13.12. RAPT Therapeutics has a fifty-two week low of $2.99 and a fifty-two week high of $27.35.

RAPT Therapeutics (NASDAQ:RAPT) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.01). On average, sell-side analysts expect that RAPT Therapeutics will post -2.93 EPS for the current year.

Institutional Investors Weigh In On RAPT Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. FMR LLC increased its stake in shares of RAPT Therapeutics by 7.4% during the 3rd quarter. FMR LLC now owns 4,499,293 shares of the company’s stock worth $74,778,000 after purchasing an additional 308,804 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of RAPT Therapeutics by 21.2% during the 1st quarter. Vanguard Group Inc. now owns 2,492,850 shares of the company’s stock worth $22,386,000 after purchasing an additional 436,629 shares during the last quarter. Perceptive Advisors LLC increased its stake in shares of RAPT Therapeutics by 11.4% during the 4th quarter. Perceptive Advisors LLC now owns 2,139,950 shares of the company’s stock worth $53,178,000 after purchasing an additional 219,292 shares during the last quarter. Kingdon Capital Management L.L.C. increased its stake in shares of RAPT Therapeutics by 55.3% during the 1st quarter. Kingdon Capital Management L.L.C. now owns 1,500,000 shares of the company’s stock worth $13,470,000 after purchasing an additional 534,172 shares during the last quarter. Finally, Braidwell LP increased its stake in shares of RAPT Therapeutics by 10.0% during the 3rd quarter. Braidwell LP now owns 1,082,512 shares of the company’s stock worth $17,991,000 after purchasing an additional 98,112 shares during the last quarter. 99.09% of the stock is owned by institutional investors.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.